Sanyuan Biotechnology(SZ:301206) Xin Lang Zheng Quan·2025-10-31 05:17Core Viewpoint - San Yuan Bio is a leading enterprise in the global erythritol industry, established in 2007 and listed on the Shenzhen Stock Exchange in 2022, with a focus on the research, production, and sales of erythritol and its compound products [1] Financial Performance - In Q3 2025, San Yuan Bio reported revenue of 476 million yuan, ranking 19th among 24 companies in the industry, while the top company, Meihua Biological, achieved revenue of 18.215 billion yuan [2] - The net profit for the same period was 67.2847 million yuan, also ranking 19th, with the industry leader, Xinhecheng, reporting a net profit of 5.354 billion yuan [2] Financial Ratios - As of Q3 2025, San Yuan Bio's debt-to-asset ratio was 3.73%, significantly lower than the industry average of 28.46%, down from 5.03% year-on-year [3] - The gross profit margin for the same period was 16.15%, an increase from 10.30% year-on-year, but still below the industry average of 28.77% [3] Executive Compensation - The chairman, Nie Zaijian, received a salary of 800,000 yuan in 2024, an increase of 77,200 yuan from the previous year [4] - The general manager, Cheng Baohua, saw his salary rise to 765,000 yuan, up by 102,600 yuan from 2023 [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 3.67% to 15,800, while the average number of circulating A-shares held per account increased by 3.81% to 8,248.95 [5]